文献速递甲状腺疾病

甲状腺癌放射性碘治疗后唾液腺与泪腺功能障碍:START研究6个月随访结果

Dysfunction of the Salivary and Lacrimal Glands After Radioiodine Therapy for Thyroid Cancer: Results of the START Study After 6-Months of Follow-Up.
PubMed 文献 · Thyroid · 2023-06-23

这项队列研究纳入136例分化型甲状腺癌(DTC)患者,分别接受1.1 GBq(44例)和3.7 GBq(92例)的131I治疗,在基线(T0)和6个月后(T6)评估唾液腺与泪腺功能。结果显示治疗后口干感和眼干患者数较基线显著增多,唾液腺平均剂量每增加1 Gy,口干感OR=1.43(CI 1.02至2.04),刺激唾液流率ß=-0.08(CI -0.12至-0.02)mL/min,唾液钾浓度ß=1.07(CI 0.42至1.71)mmol/L。

要点

  • 131I治疗后6个月口干感和眼干患者数较基线显著增多。
  • 唾液腺平均剂量每增加1 Gy,口干感OR=1.43(CI 1.02至2.04)。
  • 唾液腺平均剂量每增加1 Gy,刺激唾液流率ß=-0.08(CI -0.12至-0.02)mL/min。

核心结论

  • 本研究为131I治疗唾液腺吸收剂量与DTC患者6个月后唾液腺/泪腺功能障碍的关系提供了新知识。
  • 尽管发现部分功能障碍,结果未显示131I治疗后有明显临床障碍。
  • 研究提高对唾液腺障碍危险因素的认识,并呼吁更长随访。

研究设计与样本

  • 队列研究,纳入136例接受131I治疗的DTC患者,其中44例接受1.1 GBq、92例接受3.7 GBq。
  • 唾液腺吸收剂量采用基于热释光剂量计测量的剂量学重建方法估算。
  • 在基线(T0,即131I治疗前即刻)和6个月后(T6)用经验证问卷和唾液采样(含和不含刺激)评估唾液腺与泪腺功能。
  • 统计分析包括描述性分析和随机效应多变量logistic与线性回归。

主要发现

  • T0与T6之间腮腺疼痛程度无差异,唾液分泌减少患者数也无差异,但治疗后口干感和眼干患者数较基线显著增多。
  • 年龄、绝经、抑郁和焦虑症状、系统性疾病史、过去三个月未服用止痛药与唾液腺或泪腺障碍显著相关。
  • 调整上述变量后,131I暴露与唾液腺障碍显著相关:唾液腺平均剂量每增加1 Gy,口干感OR=1.43(CI 1.02至2.04)。
  • 唾液腺平均剂量每增加1 Gy,刺激唾液流率ß=-0.08(CI -0.12至-0.02)mL/min。
  • 唾液腺平均剂量每增加1 Gy,唾液钾浓度ß=1.07(CI 0.42至1.71)mmol/L。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Understanding of changes in salivary and lacrimal gland functions after radioactive iodine therapy (131I-therapy) remains limited, and, to date, no studies have evaluated dose-response relationships between absorbed dose from 131I-therapy and dysfunctions of these glands. This study investigates salivary/lacrimal dysfunctions in differentiated thyroid cancer (DTC) patients six months after 131I-therapy, identifies 131I-therapy-related risk factors for salivary/lacrimal dysfunctions, and assesses the relationships between 131I-therapy radiation dose and these dysfunctions. Methods: A cohort study was conducted involving 136 DTC patients treated by 131I-therapy of whom 44 and 92 patients received 1.1 and 3.7 GBq, respectively. Absorbed dose to the salivary glands was estimated using a dosimetric reconstruction method based on thermoluminescent dosimeter measurements. Salivary and lacrimal functions were assessed at baseline (T0, i.e., immediately before 131I-therapy) and six months later (T6) using validated questionnaires and salivary samplings, with and without stimulation of the salivary glands. Statistical analyses included descriptive analyses and random-effects multivariate logistic and linear regressions. Results: There was no difference between T0 and T6 in the level of parotid gland pain, nor was there difference in the number of patients with hyposalivation, but there were significantly more patients with dry mouth sensation and dry eyes after therapy compared with baseline. Age, menopause, depression and anxiety symptoms, history of systemic disease, and not taking painkillers in the past three months were found to be significantly associated with salivary or lacrimal disorders. Significant associations were found between 131I-exposure and salivary disorders adjusted on the previous variables: for example, per 1-Gy increase in mean dose to the salivary glands, odds ratio = 1.43 [CI 1.02 to 2.04] for dry mouth sensation, ß = -0.08 [CI -0.12 to -0.02] mL/min for stimulated saliva flow, and ß = 1.07 [CI 0.42 to 1.71] mmol/L for salivary potassium concentration. Conclusions: This study brings new knowledge on the relationship between the absorbed dose to the salivary glands from 131I-therapy and salivary/lacrimal dysfunctions in DTC patients six months after 131I-therapy. Despite the findings of some dysfunctions, the results do not show any obvious clinical disorders after the 131I-therapy. Nevertheless, this study raises awareness of the risk factors for salivary disorders, and calls for longer follow-up. Clinical Trials Registration: Number NCT04876287 on the public website (ClinicalTrials.gov).

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Baudin C, Bressand A, Buffet C, et al. Dysfunction of the Salivary and Lacrimal Glands After Radioiodine Therapy for Thyroid Cancer: Results of the START Study After 6-Months of Follow-Up. Thyroid. 2023. PMID: 37300484. doi:10.1089/thy.2023.0090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。